CompletedNot Applicable

Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer

Sweden118 participantsStarted 2015-05

Plain-language summary

The study's aim is to define imaging and molecular bio-markers for prediction of radiotherapy response of squamous cell carcinomas, in an early treatment phase.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Morphologically (pathology or cytology) verified, previously untreated squamous cell carcinoma (SCC) of the oral cavity, oropharynx, uterine cervix, oesophagus or lung.
✓. The patient should be planned for treatment with radiotherapy alone or in combination with concomitant medical therapy
✓. The tumour shall be radiologically and/or visually identifiable and accessible for biopsy without the need for general anaesthesia or other major interventions
✓. The patient must be at least 18 years of age, able to understand the given information and, leave a written informed consent to participate

Exclusion criteria

✕. The patient is unwilling to participate in the study
✕. Patients with adjuvant post-operative radiotherapy (i.e. no visible remaining tumour)
✕. Pregnancy or lactation
✕. Contraindications to investigations with MRI, gadolinium contrast or PET-tracers
✕. Patients with an estimated glomerular filtration rate (GFR) \<60 ml/min/1.73m2.
✕. Severe co-morbidities that are judged to significantly compromise survival in a two-years perspective.

What they're measuring

Loco regional control

Timeframe: 2 years

Trial details

NCT IDNCT02379039

SponsorUmeå University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-05

View on ClinicalTrials.gov More Squamous Carcinoma trials